Analysis
Attovia Therapeutics priced its upsized Nasdaq IPO at $17 per share this week, with the SEC declaring its registration statement effective on August 4 ahead of trading beginning under the ticker ATTO. The company's lead pipeline candidate, an anti-IL-31 therapeutic targeting chronic pruritic diseases, is already in clinical development, with two additional candidates -- for atopic dermatitis and inflammatory bowel disease -- in IND-enabling studies.
Latigo Biotherapeutics is close behind with its own Nasdaq filing, advancing two Nav1.8 inhibitors aimed at the large and commercially significant acute and chronic pain markets. The company has Phase III trials planned for its lead candidate in the second half of 2026, with topline results anticipated in the second half of 2027, alongside an ongoing Phase II proof-of-concept study for a second candidate.
Both filings are useful evidence for the broader biotech-IPO-window-reopening thesis that's been building through the summer: rather than speculative, pre-clinical-stage companies rushing to capture investor enthusiasm, the current wave of biotech listings is filled with companies carrying defined, disclosed clinical trial timelines and named drug targets -- a meaningfully higher underwriting bar than earlier biotech IPO cycles.
For venture firms with immune-disease, dermatology or pain-management portfolio companies specifically, Attovia and Latigo's reception in the public market over their first few weeks of trading is a direct read on what disclosure standard and trial-stage maturity investors are currently willing to underwrite at IPO.
What to watch: how Attovia trades in its first month versus its $17 IPO price, and whether Latigo's filing converts into a priced IPO on a similar timeline, which together would be the clearest signal yet that clinical-stage biotech -- not just AI-adjacent drug discovery -- has a genuinely open public listing window right now.
